Skip to main content
SpringerLink
Log in

Adalimumab/etanercept

Urticaria, urticarial erythema and lack of efficacy: 3 case reports

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Demirkan FG, et al. Toward the integration of biosimilars into pediatric rheumatology: adalimumab ABP 501 experience of PeRA research group. Expert Opinion on Biological Therapy 22: 197-202, No. 2, Feb 2022. Available from: URL: http://doi.org/10.1080/14712598.2021.2002296

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Adalimumab/etanercept. Reactions Weekly 1934, 17 (2022). https://doi.org/10.1007/s40278-022-28398-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-28398-9

Search

Navigation